Cidara Therapeutics Beat Consensus Estimates
Thursday, May 8, 2025 at 4:15 PM ET
Cidara Therapeutics (CDTX) reported a loss of $1.66 per share on revenue of $0.00 million for the first quarter ended March 2025. The consensus estimate was a loss of $5.45 per share. The company beat consensus estimates by 69.54% while revenue fell 100.00% compared to the same quarter a year ago.
Cidara is developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases.
Earnings Whisper Grade
Power Rating
-
-
Reported Earnings
$-1.66
Earnings Whisper®
-
Consensus Estimate
$-5.45
Earnings Surprise
Earnings Growth
Reported Revenue
-
Revenue Estimate
-
Revenue Surprise
Revenue Growth